Now accepting Telehealth appointments. Schedule a virtual visit.

Who is myo-inositol for? And who should stay away from it?

Who is myo-inositol for? And who should stay away from it

Many brands of myo-inositol are on the market, some marketed specifically for female fertility.

Myo-inositol is one of the most widely advertised and used over-the-counter supplements in female infertility. Yet, as we on previous occasions have pointed out in the VOICE, it is, unfortunately, frequently used inappropriately. Widely advertised by manufacturers as “supportive of healthy ovarian function,” there is, indeed, really little evidence in the literature for such a statement.

Myo-inositol may help IVF patients with PCOS

A review of the literature offers a very different picture: The reality is that absolutely no credible evidence exists that myo-inositol in general improves ovarian function. There is, however, moderate evidence that this supplement may have beneficial effects on IVF outcomes in women with classical polycystic ovary syndrome (PCOS). This, of course, means that myo-inositol should not be used by every female trying to conceive but only by women with classical PCOS phenotype.

Women with low androgens shouldn't take myo-inositol

Why is this such an important conclusion? Because for many infertile women, supplementation with myo-inositol is, indeed, contraindicated. The supplement industry, of course, does not want to tell you that because the industry’s interest is to sell to the widest possible market. Advertising myo-inositol just to classical PCOS patients with excessively high androgen levels, would offer only a much smaller potential target population.

But it is the ability of myo-inositol to lower testosterone levels that makes this supplement an effective treatment in classical PCOS patients. One recent study demonstrated a testosterone declines of more than 50% after such supplementation (Regidor et al., Horm Med Biol Clin Invest 34(2), March 2, 2018). In hyperandrogenic classical PCOS patient, this supplement, therefore, does, indeed, appear indicated (the recommended dosage in the study was 4,000mg/day).

But hyper-androgenism (high testosterone) is almost exclusively only a problem of classical PCOS patients. In all other infertile patients, myo-inositol will lower androgens from normal into abnormally low levels or in women with premature ovarian aging (POA), also called occult primary ovarian insufficiency (oPOI), and women with hypo-androgenic PCOS-like phenotypes (H-PCOS), both already based on their diagnoses hypo-androgenic, supplementing such patients will lower already low testosterone levels even further. And since ovaries need good androgen levels in order to produce good egg numbers and good egg quality, administration of myo-inositol in such patients will achieve exactly the opposite effects on ovaries as desired.

Myo-inositol and DHEA have opposite effects

Aggressive campaigns by various myo-inositol manufacturers and, often, lack of information on the effects of various supplements on female infertility by colleagues, have recently led to a rapidly growing number of female patients coming to CHR who at the same time are taking supplements that oppose each other in their respective functions and, therefore, outweigh each other in their effect on ovaries. The best example are women with POA/oPOI and H-PCOS who, now, by many IVF centers are increasingly supplemented with androgens (often dehydroepiandrosterone, DHEA); yet, at the same time, were advised to initiate supplementation with myo-inositol. DHEA and myo-inositol, of course, make absolutely no sense together in the same patient because DHEA is supplemented to increase testosterone levels in ovaries, while myo-inositol is given to reduce the same. Beware!

This is a part of the February 2020 issue of CHR VOICE.

Norbert Gleicher, MD

Norbert Gleicher, MD, FACOG, FACS

Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned specialist in reproductive endocrinology, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.

Follow on LinkedIn    

Watch his videos on YouTube    


We have helped women bring over
17,800 babies into the world.



You Might Also Enjoy...

The Voice June 2022

We are pleased to present here the June issue of the CHR VOICE, after which we traditionally start a two-month summer hiatus for this newsletter, returning to our regular monthly publication schedule with the start of the new 2022-2023...

The Voice May 2022

April was a hectic month at the CHR because the deadline period for abstract submission to the Annual Meeting of the ASRM is always hectic.

The Voice April 2022

March was an unusually busy month at the CHR and not only clinically. CHR’s investigators saw several important papers published, with one in NATURE Medicine, in detail presented in the March issue of the VOICE, receiving unusual media attention

The Voice March 2022

With Spring per schedule knocking on the door, the mood in the world feels anything but spring-like. The deadly and cruel Russian war machine is already for weeks invading the independent country of Ukraine.

The Voice February 2022

In the shortest and traditionally coldest month of the year, we welcome you to the February issue of our monthly newsletter. Hopefully, history will show that we reached a point in the Covid-19 pandemic with more hope than at any time slot before.